The serotonin system has recently emerged as an important player in the appearance of l-
DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it …

Selective activation of 5-HT1 receptors has been shown to produce near to full suppression
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …

Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …

In patients with Parkinson's disease, the therapeutic efficacy of l-DOPA medication is
gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually …

The administration of l-DOPA is the standard treatment for Parkinson's disease (PD).
However, the symptomatic relief provided by long-term administration may be compromised …

A rapid and excessive increase in extracellular dopamine (DA) after L-DOPA administration
is considered one of the major causes for L-DOPA-induced peak-dose dyskinesia …

Marked fluctuation of dopamine concentration in the striatum following long-term l-DOPA
administration contributes to the development of l-DOPA-induced motor complications …

Long-term administration of levodopa (L-DOPA) to patients with Parkinson's disease (PD)
commonly results in involuntary dyskinetic movements, as is known for L-DOPA-induced …

Serotonin transporter blockade with selective serotonin reuptake inhibitors (SSRIs) was
recently shown to counteract L-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA) …

In the recent years, the serotonin system has emerged as a key player in the induction of l-
DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin …